Solventum (SOLV) Expected to Post Quarterly Earnings on Wednesday

Solventum (NYSE:SOLV) is expected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Solventum to announce earnings of $1.90 per share and revenue of $2.1540 billion for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.13. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 earnings per share. On average, analysts expect Solventum to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Solventum Price Performance

SOLV opened at $87.95 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The company has a market cap of $15.23 billion, a price-to-earnings ratio of 10.78, a price-to-earnings-growth ratio of 1.32 and a beta of 0.60. The stock has a fifty day simple moving average of $78.63 and a two-hundred day simple moving average of $74.25. Solventum has a 12-month low of $62.38 and a 12-month high of $88.65.

Hedge Funds Weigh In On Solventum

Hedge funds have recently added to or reduced their stakes in the company. Boston Partners boosted its holdings in Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Solventum during the 3rd quarter valued at $42,393,000. Raymond James Financial Inc. boosted its stake in shares of Solventum by 116.5% in the 3rd quarter. Raymond James Financial Inc. now owns 702,411 shares of the company’s stock worth $51,276,000 after buying an additional 378,024 shares during the last quarter. Zimmer Partners LP purchased a new position in shares of Solventum in the 3rd quarter worth $20,075,000. Finally, AQR Capital Management LLC grew its holdings in shares of Solventum by 82.0% in the fourth quarter. AQR Capital Management LLC now owns 469,288 shares of the company’s stock worth $37,186,000 after acquiring an additional 211,440 shares during the period.

Analyst Ratings Changes

SOLV has been the subject of a number of recent research reports. Wedbush began coverage on shares of Solventum in a research report on Friday, May 15th. They set an “outperform” rating and a $94.00 price target for the company. KeyCorp upped their price target on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Piper Sandler lowered their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Stifel Nicolaus dropped their target price on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, UBS Group upgraded Solventum from a “neutral” rating to a “buy” rating and set a $95.00 price target for the company in a report on Tuesday, July 28th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $86.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.